CSF Biomarker Comparison Across Neurodegenerative Diseases

Overview

flowchart TD
    CSF["CSF"] -->|"involved in"| Glymphatic_Pathway["Glymphatic Pathway"]
    CSF["CSF"] -->|"contains"| PD_ProS["PD_ProS"]
    CSF["CSF"] -->|"activates"| AQP4["AQP4"]
    CSF["CSF"] -->|"inhibits"| MELANOMA["MELANOMA"]
    CSF["CSF"] -->|"regulates"| TAU["TAU"]
    CSF["CSF"] -->|"interacts with"| SYK["SYK"]
    CSF["CSF"] -->|"activates"| SYK["SYK"]
    CSF["CSF"] -->|"interacts with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    CSF["CSF"] -->|"phosphorylates"| NEURODEGENERATION["NEURODEGENERATION"]
    CSF["CSF"] -->|"exacerbates"| NEURODEGENERATION["NEURODEGENERATION"]
    CSF["CSF"] -->|"interacts with"| MICROGLIAL_ACTIVATION["MICROGLIAL ACTIVATION"]
    CSF["CSF"] -->|"biomarker for"| ALZHEIMER["ALZHEIMER"]
    CSF["CSF"] -->|"regulates"| MICROGLIA["MICROGLIA"]
    CSF["CSF"] -->|"phosphorylates"| ALZHEIMER["ALZHEIMER"]
    style CSF fill:#4fc3f7,stroke:#333,color:#000

Cerebrospinal fluid (CSF) biomarkers provide direct molecular insights into central nervous system pathology and are essential for differential diagnosis of neurodegenerative diseases. This page compares key CSF biomarkers across Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)^{1Cerebrospinal fluid biomarker analysis: recent updates and recommendations for Alzheimer's disease2020 · Mol Neurodegener · PMID 32428553Open reference2CSF biomarkers in neurodegenerative diseases: clinical utility and approach2022 · Nat Rev Neurol · PMID 35872025Open reference}.

Core CSF Biomarker Classes

1. Tau-Related Biomarkers

Total Tau (t-Tau)

• What it measures: Total tau protein reflecting neuronal injury

• AD: Elevated (sensitivity ~80%, specificity ~70%)

• PD: Typically normal or mildly elevated

• ALS: Elevated in advanced disease

• FTD: Variable, often normal in pure FTD

Phosphorylated Tau (p-Tau)

• What it measures: Hyperphosphorylated tau indicating NFT pathology

• p-Tau181: Most established, AD-specific (sensitivity 85%, specificity 85%)^{3CSF biomarkers vs FDG-PET: Agreement and prognostic value in the Swedish BioFINDER study2022 · Alzheimers Dement · PMID 35229096Open reference}

• p-Tau217: Highest accuracy for AD (sensitivity 90%, specificity 88%)^{4Discriminative accuracy of plasma p-tau217 for Alzheimer disease across the cognitive continuum2021 · JAMA Neurol · PMID 34554107Open reference}

• p-Tau231: Earliest detector in preclinical AD^{5CSF p-tau231 performs better than p-tau181 and p-tau217 in discriminating AD from other neurodegenerative diseases2020 · Nat Commun · PMID 33204670Open reference}

2. Amyloid Biomarkers

Aβ42/Aβ40 Ratio

• What it measures: Amyloid plaque pathology

• AD: ↓ Aβ42, ↓ Aβ40 ratio (sensitivity 80%, specificity 75%)^{6Combining cerebrospinal fluid biomarkers with brain amyloid PET for differential diagnosis of dementia2022 · JAMA Neurol · PMID 35872025Open reference}

• PD: Typically normal

• ALS: Typically normal

• FTD: Normal in pure FTD; may be abnormal with AD comorbidity

3. Neurodegeneration Markers

Neurofilament Light Chain (NfL)

• What it measures: Neuroaxonal injury severity

• AD: Moderately elevated

• PD: Elevated in PD with dementia (PDD)

• ALS: Markedly elevated (strongest marker for ALS)^{7Neurofilament light chain in blood and CSF as a biomarker in ALS2022 · Nat Rev Neurol · PMID 35792118Open reference}

• FTD: Elevated, correlates with disease progression

Neurogranin (Ng)

• What it measures: Synaptic degeneration

• AD: Strongly elevated

• PD: Mild elevation

• ALS: Elevated

• FTD: Variable

4. Synuclein Biomarkers

Alpha-Synuclein

• What it measures: Alpha-synuclein pathology

• Total α-syn: Decreased in synucleinopathies^{8Cerebrospinal fluid biomarkers in Parkinson's disease: from the limbic system to the brain2019 · Brain · PMID 31740947Open reference}

• Real-time quaking-induced conversion (RT-QuIC): Positive in ~95% of PD, ~55% of AD

• PD: ↓ Total, RT-QuIC often positive

• DLB: ↓ Total, RT-QuIC positive

• AD/ALS/FTD: Typically normal

5. TDP-43 Biomarkers

TDP-43

• What it measures: TDP-43 proteinopathy

• ALS: Elevated in CSF (sensitivity ~75%, specificity ~80%)^{9TDP-43 in cerebrospinal fluid of patients with ALS and FTLD: a systematic review and meta-analysis2020 · J Neurol Neurosurg Psychiatry · PMID 31307191Open reference}

• FTD: Elevated, especially in ALS-FTD spectrum

• AD/PD: Typically normal

6. Glial Markers

Glial Fibrillary Acidic Protein (GFAP)

• What it measures: Astrocyte activation

• AD: Elevated

• PD: Typically normal

• ALS: Elevated

• FTD: Variable

Diagnostic Utility by Disease

Alzheimer’s Disease (AD)

Key biomarker profile: ↓ Aβ42/Aβ40 + ↑ p-tau181/217 + ↑ t-tau

• Aβ42/Aβ40 ratio: Best for identifying amyloid pathology

• p-Tau217: Highest discriminative accuracy vs. other dementias

• NfL: Correlates with disease progression

• Neurogranin: Specific marker of synaptic dysfunction^{10Neurogranin in cerebrospinal fluid and blood as a biomarker of synaptic dysfunction2015 · JAMA Neurol · PMID 25929252Open reference}

Parkinson’s Disease (PD)

Key biomarker profile: ↓ total α-syn + normal p-tau/t-tau

• α-syn RT-QuIC: Sensitive for prodromal PD

• NfL: Prognostic marker for cognitive decline

• p-Tau/NfL ratio: May distinguish PD from atypical parkinsonism

Amyotrophic Lateral Sclerosis (ALS)

Key biomarker profile: ↑↑ NfL + ↑ TDP-43

• NfL: Strongest diagnostic and prognostic biomarker^{2CSF biomarkers in neurodegenerative diseases: clinical utility and approach2022 · Nat Rev Neurol · PMID 35872025Open reference}0

• pNfH: Correlates with disease progression

• TDP-43: Reflects pathological burden

• Chitinase-3-like protein 1 (YKL-40): Elevated, marker of neuroinflammation

Frontotemporal Dementia (FTD)

Key biomarker profile: ↑ NfL + normal AD biomarkers

• NfL: Correlates with disease severity

• YKL-40: Elevated in some subtypes

• Progranulin: Genetic forms have distinct profiles

Cross-Disease Comparison

Biomarker Panels for Differential Diagnosis

AD vs. FTD vs. ALS

• AD: Aβ42/Aβ40↓ + p-Tau↑↑ + t-Tau↑

• FTD: Aβ42/Aβ40↔ + p-Tau↔ + NfL↑ + TDP-43↔

• ALS: NfL↑↑↑ + TDP-43↑ + p-Tau↔

PD vs. Atypical Parkinsonism (PSP/CBS)

• PD: α-syn↓ + NfL↔/↑ + p-Tau↔

• PSP/CBS: NfL↑↑ + p-Tau↔ + t-Tau↑

Clinical Applications

Diagnostic Workup

1. Suspected AD: Order Aβ42/Aβ40, p-Tau181, t-Tau

2. Suspected PD/LBD: Order α-syn RT-QuIC, NfL

3. Suspected ALS: Order NfL, pNfH, TDP-43

4. Suspected FTD: Order NfL, rule out AD with p-Tau

Prognostic Markers

• NfL: Strongest prognostic marker across all diseases

• p-Tau: Correlates with cognitive decline in AD

• Neurogranin: Predicts cognitive progression in AD

Monitoring Therapeutic Response

• NfL: Used as outcome in ALS clinical trials

• p-Tau: Reduced by anti-amyloid therapies in AD trials^{2CSF biomarkers in neurodegenerative diseases: clinical utility and approach2022 · Nat Rev Neurol · PMID 35872025Open reference}1

Limitations

• Assay variability: Different platforms have different cutoffs

• Overlap: Biomarkers can be elevated in multiple conditions

• Sensitivity/specificity: No single biomarker is pathognomonic

• Dynamic range: Some biomarkers have ceiling effects

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy